UNITED
STATES


SECURITIES
AND EXCHANGE COMMISSION


WASHINGTON,
D.C. 20549





FORM
10-KSB






[X]
            ANNUAL
      REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
      1934For
      the fiscal year ended November
      30, 2007[  ]
            TRANSITION
      REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
      ACTFor the transition
      period from _________ to _______Commission
      file number 333-140438




RM Health
      International, Inc.(Name
      of small business issuer in its
charter)




Nevada
            n/a(State or other
      jurisdiction of incorporation or organization)
            (I.R.S. Employer
      Identification No.)36
      Palazzo Terrace,Henderson,
      Nevada
            89074(Address
      of principal executive offices)
            (Zip
      Code)




Issuer’s
      telephone number:  (702)
      612-3014Securities
      registered under Section 12(b) of the Exchange Act:Title
      of each class
            Name
      of each exchange on which registeredNone
            Not ApplicableSecurities
      registered under Section 12(g) of the Exchange Act:Title
      of each class
            Name
      of each exchange on which registeredNone
            Not
Applicable




Check
whether the Issuer (1) filed all reports required to be filed by Section 13 or
15(d) of the Securities Exchange Act during the past  12 months (or
for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90
days.    Yes
[X]       No
[   ]





Check if
disclosure of delinquent filers in response to Item 405 of Regulation S-B is not
contained in this form, and no disclosure will be contained, to the best of
registrant’s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-KSB or any amendment to
this Form 10-KSB [   ]





Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).   Yes [ x ]   No
[   ]





State
issuer’s revenue for its most recent fiscal year.  $0





State the
aggregate market value of the voting and non-voting common equity held by
non-affiliates computed by reference to the average bid and asked price of such
common equity, as of a specified date within the past 60 days.  Not available.





State the
number of shares outstanding of each of the issuer’s classes of common equity,
as of the latest practicable date. 6,759,300 Common Shares as of
February 27, 2008.





Transitional
Small Business Disclosure Format (Check One):  Yes: __; No X




Table of Contents





TABLE OF
CONTENTS





PagePART
      IItem 1.
            Description of Business
            3Item 2.
            Description of Property
            11Item 3.
            Legal Proceedings
            11Item 4.
            Submission of Matters to a Vote of Security
      Holders
            11PART
      IIItem 5.
            Market for Common Equity and Related Stockholder
      Matters
            11Item 6.
            Plan of Operation
            13Item 7.
            Financial Statements
            17Item 8.
            Changes In and Disagreements With Accountants on Accounting and
      Financial Disclosure
            18Item 8A.
            Controls and Procedures
            18Item 8B.
            Other Information
            19PART
      IIIItem 9.
            Directors, Executive Officers, Promoters and Control Persons;
      Compliance With Section 16(a) of the Exchange Act
            19Item 10.
            Executive Compensation
            21Item 11.
            Security Ownership of Certain Beneficial Owners and Management
      and Related Stockholder Matters
            23Item 12.
            Certain Relationships and Related
    Transactions
            24Item 13.
            Exhibits
            24Item 14.
            Principal Accountant Fees and Services
            25




2
 Table of Contents








PART I




Item 1.   Description of Business




Overview





We were
incorporated on March 28, 2006 as RM Health International, Inc., a Nevada
corporation, and we do business under the name as “RM Health”. We plan to
provide a comprehensive education resource and online purchase facility. The
education component is an important part of the marketing plan as the need for
consumer education in the marketplace is evident. Finding the optimal balance of
price, benefits and levels of understanding drive consumer choice among natural
and organic products and provide an edge over conventional methods of retail
sales.





The RM
Health business model is based on creating a web based storefront and education
center targeted at the Lifestyles of Health and Sustainability (“LOHAS”)
consumers LOHAS demographic. Custom content is offered to attract traffic to the
site. Purchase options presented are based on the education content for specific
conditions or categories. RM Health is the conduit that brings together the
independent groups of customers, providers, advertisers and affiliates. RM
Health creates reseller and private label agreements with specific providers and
suppliers who meet our criteria. RM Health receives a profit on each order from
the RM Health site or its affiliates. Orders are processed through the RM Health
site and transaction engine


then
sent to the supplier who provisions (drop ships) the order directly to the
customer. RM Health will create a membership program that will encourage
customer loyalty with expanded benefits and programs. Since the RM Health
consumer is concerned with lifestyle issues there are multiple opportunities for
RM Health to create relationships and generate revenue from advertisers and
affiliates such as Gaiam.com. RM Health is not limited in the number of
relationships that can be created. Advertising value will be driven as traffic
to the site increases and the size of the membership database
increases.





Principal
Products and Services





These are
the top 20 sales categories of products and supplements. RM Health will focus
its efforts on locating and offering for sale superior products within the
following specific categories:





1.
Cleanse.


2.
Digestive and Gastronomical Aids.


3.
Diabetes management.


4. Immune
System support.


5. Bone
and Joint (Osteoporosis and Arthritis).


6.
Circulatory System.


7.
Natural products for appearance.


8.
Concentration.


9. Sports
and Fitness.


10.
Weight Management and control.




3
 Table of Contents




11.
Respiratory System.


12.
Glandular System.


13.
Stress Management aids.


14.
Prostate Support.


15.
Women’s Health and Support.


16.
Increased Energy and Fatigue.


17. Bowl
elimination and support.


18.
Improving Sexual performance Male and Female.


19.
Improving Cardiovascular Health.


20.
Controlling Blood pressure and blood sugar support.





Supplemental
products – books and CD’s on health and lifestyle.





Since the
consumer searches for products by benefit, the navigation for the site will be
built around these benefits. Since some products have multiple benefits the
consumer will be offered program choices. At each product selection they will be
given a one off non-member price, member price, and automatic recurring price.
Each particular benefit category will also come with the appropriate information
on the product, trends, and other lifestyle suggestions for improvement.
Complimentary products will also be suggested according to the benefit
profile.





The RM
Health site is designed to be simple to navigate identifying the two types of
visitors to the site, new visitors, and existing members. New visitors will be
initially directed to the membership area where they can sign up for the free
membership or premium (pay). Existing members are taken straight to their
account information, preferences and order profile.





Customers
are never more than a single click away from being able to order products, refer
their friends and associates or join the membership program. The operating goal
of the site is to have each and every visitor participate in one form or another
either by ordering product or becoming part of the database asset.





Planned
Product Line





RM Health
is not restricted to any one particular product line which leaves the company
free to offer the best product in each category of consumer interest. RM Health
does extensive research on each and every product for efficacy and benefits.
Only category leaders are offered in the RM Health portfolio. The following
companies will serve as the suppliers of our initial product line:





Ayush Herbs, Inc. –The
company provides the highest quality of herbal products, vitamins, minerals and
enzymes available. All the products are naturally grown in the Himalayan habitat
without the use of pesticides and other chemicals.




Cyto-Matrix, Inc. –Cyto-Matrix strives to improve the health and wellbeing of its customers
by using the highest quality of raw materials and manufacturing products in a
state-of-the-art manufacturing facility.





4
 Table of Contents




Our
planned product line will include the following natural remedies:





(1)           High blood pressure
remedy




Product Name:
              CarditoneRetail Price
              $28.00


Description:Carditone
contains the herb Rauwolfia serpentina, which has become an important
therapeutic aid to promote healthy blood pressure. It has strong hypotensive and
sedative activity. Arjuna and rose powder have been used for centuries in
Ayurveda to support heart function, while Tribulus terrestris is considered
renal supportive. Indian coral powder is a good source of calcium and
magnesium.





Attributes:
            Vegetarian




Ingredients:Standardized extract of Rauwolfia serpentina, Arjuna, Convovulus
plericaulis, Tribulus terrestris, and Magnesium aspartate in a base of rose
powder, Boerhaavia diffusa and Indian coral powder.  Amount per
tablet: Convolvuvus P 100mg, Arjuna 100mg, Tribulus T 100mg, Rauwolfia
50mg





Dosage:One tablet 2
times daily or as directed by physician





(2)           High cholesterol
remedy





Product Name:
            Lipo
  matrixRetail Price
            $35.99








Description:This new
Lipo-Matrix formulation is a unique blend of botanicals and vitamins with high
grade-level evidence specifically focused on cardiovascular disease. The
ingredients and dosages have been carefully chosen to reflect the current
evidence in cardiovascular disease management.





Ingredients:For
decreasing hyperlipidemia: Policosanol; Guggul Resin Extract; Raw Garlic
Extract; Inositol hexaniacinate. For decreasing hyperhomocysteinemia: Folic
Acid; Vitamin B6; Vitamin B12.  For increasing HDL: Policosanol;
Inositol hexaniacinate.  For cardiovascular secondary prevention:
Inositol hexaniacinate; Policosanol; Raw Garlic Extract





Dosage:As recommended
by your health care provider





(3)           Women's health -
menopause





Product Name:
            Eleg femRetail Price
            $27.50








5
 Table of Contents




Description:ElegFemTM is
especially helpful for pre-menopausal and menopausal conditions. The synergistic
action of Ashoka, Dioscorea, Asparagus, Arjuna, Cissus quadrangularis and Indian
coral powder has been shown to alleviate symptoms associated with menopause.
Coral powder is a rich source of calcium and magnesium. Cissus quadrangularis
traditionally has been used to speed the healing process of bone
fractures.





Product Name:
            CarditoneRetail Price
            $28.00




Attributes:
              Vegetarian





Ingredients:Ahoka,
Dioscorea, Asparagus, Arjuna, Cissus quadrugularis, Bamboo
manna and Indian coral powder.





Dosage:One Capsule 3
times a day or as directed by your physician





(4)           Women's health -
PMS





Product Name:
            Fem matrixRetail Price
            $46.99





Description:The herbs
used in Fem-Matrix have a long history of use for the prevention and treatment
of menopausal and perimenopausal symptoms, mainly hot flushes. While Black
Cohosh, Dong Quai, Chasteberry, Wild Yam, and Red Clover extracts have
estrogen-like effects, Hesperidin and Quercetin reduces the loss of endogenous
estrogen, which is associated with the symptoms.





Ingredients:   
Black Cohosh, Dong Quai, Chasteberry, Wild Yam, Red Clover, Hesperidin and
Quercetin





Dosage:           As
recommended by your physician





(5)           Sexual Vitality
Female





Product Name:
            PurushRetail Price
            $27.50




Description:Purush is a
combination of Ayurvedic herbal aphrodisiacs based on the ancient use of these
herbs to support male sexual health. Ashwagandha helps the body to slow down
cellular aging and to combat fatigue; the anti-oxidant Amla provides energy and
vigor; Tribulus has been shown to increase testosterone levels and Shilajeet is
a mineral compound that boosts physical stamina and strengthens bone tissue.
PurushTM also contains Yohimbe, which has been traditionally used to promote
normal sexual function.





Product Name:
            CarditoneRetail Price
            $28.00




Attributes:
              Vegetarian


6
 Table of Contents





Ingredients:Standardized extracts of Ashwagandha 175mg, Macuna pruriens 20mg,
Tribulus terrestis 50mg, Shilajit 25mg, Saw Palmeto 25mg, Saffron, Amla,
Shilajeet, Pippli, Licorice, Bacopa monnieri, Bala talmakhana, Akarkara, Muira
puma, Colchicum and Yohimbe





Dosage:As recommended
by your physician





(6)           Male vitality -
Remedy




Product Name:
            PurushRetail Price
            $27.50




Description:  Purush
is a combination of Ayurvedic herbal aphrodisiacs based on the ancient use of
these herbs to support male sexual health. Ashwagandha helps the body to slow
down cellular aging and to combat fatigue; the anti-oxidant Amla provides energy
and vigor; Tribulus has been shown to increase testosterone levels and Shilajeet
is a mineral compound that boosts physical stamina and strengthens bone tissue.
PurushTM also contains Yohimbe, which has been traditionally used to promote
normal sexual function.





Attributes:
            Vegetarian





Ingredients:Standardized extracts of Ashwagandha 175mg, Macuna pruriens 20mg, Tribulus
terrestis 50mg, Shilajit 25mg, Saw Palmeto 25mg, Saffron, Amla, Shilajeet,
Pippli, Licorice, Bacopa monnieri, Bala talmakhana, Akarkara, Muira
puma, Colchicum and Yohimbe




Dosage:Two Capsules at
bedtime or 1 Capsule twice a day - Do not exceed 6 capsules a day. Discontinue 1
week after every 10 to 12 weeks, or use as directed by your
physician.





Both in
initial and repeat traffic to the RM Health site will be driven by the site’s
educational content tailored to various specific conditions and health
needs.





Completive
Business Conditions and Methods of Competition





The
market for natural and organic products/supplements continues to explode. In the
US alone
American shoppers spent $51 billion on natural and organic products in 2005
according to the
Natural Foods Merchandiser the industry’s leading publication.





Natural
products sales increased 9.1 percent across all retail and direct-to-consumer
sales channels.
Most sales -- 80.9 percent -- came from the natural retailing and mass market
channels. In
natural products stores, food sales grew 12.1 percent, and all but one of the
food categories tracked
by NFM had double-digit growth. Organic food sales grew 15.7 percent.
Supplements sales
rose 8.2 percent, and natural personal care sales increased 12.1 percent. For
the first time




7
 Table of Contents




since
1999, natural products retailers saw double-digit growth at 10.9 percent for
$25.5 billion in sales. Natural products retailers outpaced all other channels
but the Internet, which had 17.7 percent growth and reached $558 million in
sales. The largest sales categories in natural products stores were vitamins,
$3.1 billion; produce, $2.97 billion; packaged grocery, $2.48 billion; and
personal care, $2.35 billion. Organic produce sales in natural products stores
were worth $2.14 billion followed by organic packaged grocery at $1.36
billion.





There are
numerous factors driving and supporting this growth; including scientific
discoveries, nutrient
breakthroughs, changing lifestyles and demographics, rising obesity, and a
desire for wellness
personalization. The U.S. population is undergoing a dramatic shift in
demographics, as
household sizes change, the population ages and the number of minorities
increases. One of the
key factors is catering to the aging population. As a growing number of the 78
million strong baby
boomer generation is more focused on preventing certain health conditions, and
is more
likely than other generations to increase consumption of healthy foods and
beverages, and avoid
problematic ingredients such as sodium and sugar.





On the
other end of the age spectrum, opportunity will arise for new products targeting
the increasing number of 20-somethings who are just starting out on their own
and are far more adventurous in food choices.





The U.S.
nutritional supplements retail industry is a large and highly fragmented
industry. In 2004, no single industry participant accounted for more than 10% of
total industry sales. We compete primarily against other specialty retailers,
supermarkets, drugstores, mass merchants, multi-level marketing organizations
and mail order companies. This market is highly sensitive to the introduction of
new products, which may rapidly capture a significant share of the market.
Certain of our competitors may have significantly greater financial, technical
and marketing resources than we do.





We
believe that RM Health will have several advantages over traditional retail
outlets. The most important advantage for our model is the physical experience.
When going into a physical outlet the consumer is faced with a daunting
selection. Products and supplements are arranged by type not by benefit
many times leaving the customer with an overwhelming array of products to
choose from. Since education is a critical part of the buying process RM Health
has a distinct advantage in that products are arranged by benefit to the
consumer such as increased energy level, concentration, or circulation. This
helps the consumer go directly to the area of interest and receive the proper
education materials to make an informed and confident decision.


In
addition, RM Health preserves capital because the company does not have to
inventory product or be constrained by a physical footprint. Overhead is
limited to hosting and maintenance of the site, database, and transaction
engines. This places the company emphasis primarily on marketing efforts.
This model has proven successful in other consumer focused categories on the
internet.





Marketing
Plan





There are
two components to the marketing plan. The first is the external focus to attract




8
 Table of Contents




customers
and drive traffic to the site. The second is to create membership, loyalty and
referral programs once the consumer has arrived at the site.





External
Marketing





R&M
will focus most of the external marketing efforts on search engine optimization,
with specific efforts focused on the characteristics of Google the most popular
and successful search engine. The dynamics of search engine optimization (SEO)
have changed dramatically in the last few years. In the early 2000’s, search
engines have veered away from reliance on meta tags since many web sites used
inappropriate meta keywords or a technique known as keyword stuffing, in order
to increase their search engine ranking. Some search engines still take meta
tags into consideration when delivering results, though most of the major search
engines ignore them. Organic search engines such as Google and Yahoo now use up
to 100 different criteria to rank the listings on it’s search engine results
pages (SERP’s). In order to achieve prime results on the SERP’s RM Health will
purchase Google Adwords and links from partner affiliate sites that ensure
strong positioning in our niche market. In contrast, many businesses try to
optimize their sites for large numbers of highly specific keywords that indicate
readiness to buy. Overly broad search optimization can hinder marketing strategy
by generating a large volume of low-quality inquiries that cost money to handle,
yet result in little business. Focusing on desirable traffic generates better
quality sales leads, resulting in more sales. Search engine optimization can be
very effective when used as part of a smart niche marketing
strategy.





Referral
Program





RM Health
customers receive ongoing incentives to refer their friends and associates to
the site. It is important to keep in mind that particularly with LOHAS consumers
since they are “values” driven they tend to share information within their
community of associates. Customers will receive incentives to refer their
friends directly at the site and from informational emails they receive from RM
Health.





Membership
Program





All
visitors to the RM Health site will be given incentives to join a membership
program. This is a very valuable demographic so acquiring additional information
to build the database will


become a
company asset.





Automatic
Order Renewals





One of
the keys to beginning any new lifestyle regimen is maintaining consistency and
developing a habit. One of the options of membership to RM Health is automatic
order renewals that save the customer time and money. Renewal options are
offered in 3, 6, and 12 month increments. The longer the extension of the
program the greater the discount the customer receives. It is anticipated this
program will be very popular since customers are making a lifestyle commitment
and not a one off purchase.





9
 Table of Contents




Survey
Tool





Most
sites currently available on the internet are just basic virtual storefronts,
some with limited information. RM Health will be far more interactive by using a
survey tool that will help direct customers to the products and supplements
based suited for them based on lifestyle questions.





Compliance
with Government Regulation





Our
products are vitamins, minerals, herbs and other ingredients that are classified
as foods or dietary supplements and are not subject to pre-market regulatory
approval in the United States.





The
processing, formulation, manufacturing, packaging, labeling, advertising and
distribution of our products are subject to federal laws and regulation by one
or more federal agencies, including the FDA, FTC, the DOA and the EPA. These
activities are also regulated by various state, local and international laws and
agencies of the states and localities in which our products are sold. Additional
regulations may prevent or delay the introduction, or require the reformulation,
of our products, which could result in lost sales and increased costs to us. The
FDA may determine that a particular statement of nutritional support on our
products, or that we want to use on our products, is an unacceptable drug claim
or an unauthorized version of a food “health claim,” or the FDA or the FTC may
determine that particular claims are not adequately supported by available
scientific evidence. Any such regulatory determination would prevent us from
marketing particular products or using certain statements on our products which
could adversely affect our sales of those products. The FDA also could require
us to remove a particular product from the market.





We are
not able to predict the nature of such future laws, regulations, repeals or
interpretations or to predict the effect additional governmental regulation,
when and if it occurs, would have on our business in the future. Such
developments could require reformulation of certain products to meet new
standards, recalls or discontinuance of certain products not able to be
reformulated, additional record-keeping requirements, increased documentation of
the properties of certain products, additional or different labeling, additional
scientific substantiation, adverse event reporting or other new requirements.
Any such developments could increase our costs significantly and could have a
material adverse effect on our business, financial condition and results of
operations.





Employees





Our
President, Randy Weston, is currently our only employee.  Mr. Weston
devotes 5 to 10 hours per week to our business affairs.  We do not
have any full time employees.





Research
and Development Expenditures





We have
not incurred any research or development expenditures since our
incorporation.





10
 Table of Contents





Subsidiaries





We have
neither formed, nor purchased any subsidiaries since our
incorporation.





Patents
and Trademarks





We do not
own, either legally or beneficially, any patent or trademark.





Item 2.   Description of Property





We do not
own or lease any real property.





Item 3.   Legal Proceedings





As of
November 30, 2007, we were not a party to any pending legal proceeding and were
not aware of any pending legal proceeding to which any of our officers,
directors, or any beneficial holders of 5% or more of our voting securities are
adverse to us or have a material interest adverse to us.





Item 4.   Submission of Matters to a Vote of Security
Holders





No
matters were submitted to our security holders for a vote, through the
solicitation of proxies or otherwise, during the fourth quarter of the fiscal
year ended November 30, 2007.








PART II





Item 5.    Market for Common Equity and Related
Stockholder Matters





Market
Information





Our
common stock is currently quoted on the OTC Bulletin Board (“OTCBB”), which is
sponsored by the NASD.  The OTCBB is a network of security dealers who
buy and sell stock.  The dealers are connected by a computer network
that provides information on current "bids" and "asks", as well as volume
information.  As of November 30, 2007, our shares were quoted on the
OTCBB under the symbol “RMHL.”





The
following table sets forth the range of high and low bid quotations for our
common stock for each of the periods indicated as reported by the
OTCBB.  These quotations reflect inter-dealer prices, without retail
mark-up, mark-down or commission and may not necessarily represent actual
transactions.




11
 Table of Contents




Fiscal
      Year Ending November 30, 2007Quarter
      Ended
            
            High
      $
            
            Low
      $November
      30, 2007
            
            
            0
            
            0August
      31, 2007
            
            
            0
            
            0May
      31, 2007
            
            
            n/a
            
            n/aFebruary
      28, 2007
            
            
            n/a
            
            n/a





Penny
Stock





The SEC
has adopted rules that regulate broker-dealer practices in connection with
transactions in penny stocks. Penny stocks are generally equity securities with
a market price of less than $5.00, other than securities registered on certain
national securities exchanges or quoted on the NASDAQ system, provided that
current price and volume information with respect to transactions in such
securities is provided by the exchange or system. The penny stock rules require
a broker-dealer, prior to a transaction in a penny stock, to deliver a
standardized risk disclosure document prepared by the SEC, that: (a) contains a
description of the nature and level of risk in the market for penny stocks in
both public offerings and secondary trading; (b) contains a description of the
broker's or dealer's duties to the customer and of the rights and remedies
available to the customer with respect to a violation of such duties or other
requirements of the securities laws; (c) contains a brief, clear, narrative
description of a dealer market, including bid and ask prices for penny stocks
and the significance of the spread between the bid and ask price; (d) contains a
toll-free telephone number for inquiries on disciplinary actions; (e) defines
significant terms in the disclosure document or in the conduct of trading in
penny stocks; and (f) contains such other information and is in such form,
including language, type size and format, as the SEC shall require by rule or
regulation.





The
broker-dealer also must provide, prior to effecting any transaction in a penny
stock, the customer with (a) bid and offer quotations for the penny stock; (b)
the compensation of the broker-dealer and its salesperson in the transaction;
(c) the number of shares to which such bid and ask prices apply, or other
comparable information relating to the depth and liquidity of the market for
such stock; and (d) a monthly account statement showing the market value of each
penny stock held in the customer's account.





In
addition, the penny stock rules require that prior to a transaction in a penny
stock not otherwise exempt from those rules, the broker-dealer must make a
special written determination that the penny stock is a suitable investment for
the purchaser and receive the purchaser's written acknowledgment of the receipt
of a risk disclosure statement, a written agreement as to transactions involving
penny stocks, and a signed and dated copy of a written suitability
statement.





These
disclosure requirements may have the effect of reducing the trading activity for
our common stock. Therefore, stockholders may have difficulty selling our
securities.




12
 Table of Contents





Holders
of Our Common Stock





As of
November 30, 2007, we had thirty (30) holders of record of our common
stock.





Dividends





There are
no restrictions in our articles of incorporation or bylaws that restrict us from
declaring dividends. The Nevada Revised Statutes, however, do prohibit us from
declaring dividends where, after giving effect to the distribution of the
dividend:





1.
            We
      would not be able to pay our debts as they become due in the usual course
      of business; or





2.
            Our
      total assets would be less than the sum of our total liabilities, plus the
      amount that would be needed to satisfy the rights of shareholders who have
      preferential rights superior to those receiving the
      distribution.





Securities
Authorized for Issuance Under Equity Compensation Plans





As of
November 30, 2007, we had no equity compensation plans.





Item 6.  Plan of Operation





Forward-Looking
Statements




Certain
statements, other than purely historical information, including estimates,
projections, statements relating to our business plans, objectives, and expected
operating results, and the assumptions upon which those statements are based,
are “forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of
1934.   These forward-looking statements generally are identified
by the words “believes,” “project,” “expects,” “anticipates,” “estimates,”
“intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will
continue,” “will likely result,” and similar expressions.  We intend
such forward-looking statements to be covered by the safe-harbor provisions for
forward-looking statements contained in the Private Securities Litigation Reform
Act of 1995, and are including this statement for purposes of complying with
those safe-harbor provisions.  Forward-looking statements are based on
current expectations and assumptions that are subject to risks and uncertainties
which may cause actual results to differ materially from the forward-looking
statements. Our ability to predict results or the actual effect of future plans
or strategies is inherently uncertain. Factors which could have a material
adverse affect on our operations and future prospects on a consolidated basis
include, but are not limited to: changes in economic conditions,
legislative/regulatory changes, availability of capital, interest rates,
competition, and generally accepted accounting principles. These risks and
uncertainties should also be considered in evaluating forward-looking statements
and undue reliance should not be placed on such statements. We undertake no
obligation to update or revise publicly any forward-looking statements, whether
as a result of new




13
 Table of Contents




information,
future events or otherwise.  Further information concerning our
business, including additional factors that could materially affect our
financial results, is included herein and in our other filings with the
SEC.




Plan
Of Operations





Operating
Budget





For the
fiscal year beginning November 30, 2007






Rent
            $
            375.00Legal
            $
            2,800.00Accounting
            $
            2,900.00Product
      procurement
            $
            1,400.00Marketing
            $
            7600.00Website
      Development
            $
            2800.00Advertising
            $
            4,200.00$
            22,075.00




Operating
Objectives And Progress To Date





During
the first quarter of our first full fiscal year, we focused our efforts
primarily on research and on reaching a final written engagement agreement with
Dr. Jheeta, ND. (NaturoPathic Doctor).  We retained Dr. Jheeta as our
Spokesperson for our Preventative Health Systems.  In that capacity,
he serves as our principal resource for all related information concerning
product formulations, priority of health concerns, and supporting health
information.





At the
beginning of the second quarter of the current fiscal year, we reached a formal
written a manufacturing and fulfillment agreement with Ayush Herbs,
Inc.  Our relationship with Ayush Herbs, Inc. provides us with access
to proven products that will be used to form our preventative health
systems.  In addition, Ayush Herbs, Inc. will ship directly to our
customers, thereby adding simplicity and efficiency to our planned
operations.




Additional
research performed during the second quarter of this fiscal year helped us to
finalize and perfect our initial product line.  To begin our active
sales operation, we will launch the PreV-Heart Health System, a proprietary
health program featuring products manufactured by Ayush Herbs, Inc.




By the
end of the second quarter we had collected significant supporting health
information for our preventative heart health systems.  This
information has enabled us to begin building our website and the future home of
our business -- www.rmhealthinternational.com.




We had
planned to make significant progress in the development of our website during
the third quarter of this fiscal year, but we experienced significant difficulty
in locating web design




14
 Table of Contents




professionals
who were willing and able to provide the needed technical assistance at a cost
which met our budget.  The unexpectedly high cost of building our
website has slowed our progress and, in order to continue to completion, we may
need to raise additional capital.  We currently do not have any
arrangements for raising additional funds and we may not be able to obtain the
additional when required.  Due to these unexpected financial
difficulties, our business development schedule has been extended.




During
the fourth quarter, we had hoped to focus heavily on the development of our
website while continuing to build our network of advertisers and affiliates. Our
plans have been delayed due to mounting costs, a slow-down in the economy, and
increased online competition. At this time, we plan to market online as best we
can within our existing budget. Our original expectation of receiving revenue by
the first quarter of Year 2 will not be realized, and we expect to see sales
commence by the beginning of the third quarter of the current fiscal year. The
following is a current schedule of our business development goals for the next
three quarters:








By
      end of the 2nd
      Quarter of Year 2
            We
      plan to aggressively market our affiliate programs by increasing
      commissions to affiliates and by marketing our products through other
      websites.By
      end of 3rd
      Quarter of Year 2:
            We
      plan to market to affiliates and other possible resellers. We hope to use
      profits from new revenues to market directly through Google, which usually
      is the best way to increase the number of visitors to the website and to
      potentially increase the number of new sales.By
      the end of the 4th
      Quarter Year 2:
            If
      our efforts have successfully increased sales and profits, we plan to take
      our business to the next level by having all content and product systems
      in place. Ideally, this will allow us to have Dr. Jheeta begin radio talk
      shows and potentially local TV talk shows. On these programs, Dr. Jheeta
      will explain the benefit of preventative health regiments and the features
      and advantages of the products and health systems offered by RM Health.
      Through these efforts, we plan to build a growing consumer following and a
      newsletter database that will help us to further optimize our market
      efforts.





Due to
the significant constraints imposed by our limited capital resources and our
continuing difficulty in moving forward with our plan of operations at the pace
expected and desired by our management, we have also begun the difficult task of
re-evaluating our business plan and plan of
operations.    Our relatively slow progress so far, the
uncertainty regarding our ability to obtain any additional funding, and the
relatively risky overall nature of our enterprise have caused us to question
whether it continues to be commercially viable.  Although we plan to
continue with the development of our operations set forth above within the
confines of our current budget, management may also begin evaluating alternative
business opportunities which may be available




15
 Table of Contents




to
us.





Employees





We did
not have any employees as of November 30, 2007.   Our officer and
director, Randy Weston, served without compensation.





Research
and Development





As of
November 30, 2007, we have not conducted any research or
development




Purchase
and Sale of Significant Equipment





As of
November 30, 2007, we did not anticipate any purchase or sale of equipment over
the next twelve months.





Results
of Operations for the Year Ended November 30, 2007





We did
not earn any revenue during the fiscal year ended November 30, 2007 and have not
earned any revenue since our inception on March 28, 2006.





We
incurred operating expenses and a net loss in the amount of $16,108 during our
fiscal year ended November 30, 2007, compared to operating expenses and a net
loss in the amount of $10,340 during our fiscal year ended November 30, 2006 and
a total of $26,448 in operating expenses and net losses for the period from
inception (March 28, 2006) to November 30, 2007. For the period from inception
to November 30, 2007, these expenses consisted of organizational costs in the
amount of $375 and general and administrative expenses in the amount of
$26,073.





Our
losses for this period are attributable to operating expenses and a lack of
revenue.





Liquidity
and Capital Resources





As of
November 30, 2007, we had total current assets of $11,775 and total assets of
$11,775. Our current assets as of November 30, 2007 consisted of cash in the
mount of $10,775 and deposits of $1,000. Our total current liabilities as of
November 30, 2007 were $10,538, consisting of an obligation due to a related
party and accrued liabilities. As a result, on November 30, 2007, we had working
capital of $1,237.





Operating
activities used $19,970 in cash for the fiscal year ended November 30, 2007,
compared to $6,690 for the fiscal year ended November 30, 2006 and $26,660 in
total cash for the period from inception (March 28, 2006) to November 30, 2007.
Our net losses totaling $26,448 since inception were the primary component of
our negative operating cash flow. Net cash flows provided by financing
activities for the period from inception (March 20, 2006) to May 31, 2007 were
$37,435 representing proceeds from the sale of our stock and advances from




16
 Table of Contents




a related
party.





We are a
development stage corporation and have not generated any revenue to date from
our activities.





Off
Balance Sheet Arrangements





As of
November 30, 2007, there were no off balance sheet arrangements.





Going
Concern





We have
not attained profitable operations and are dependent upon obtaining financing to
pursue exploration activities. For these reasons our auditors stated in their
report that they have substantial doubt we will be able to continue as a going
concern.





Our
ability to continue as a going concern is dependent our generating cash from the
sale of our common stock and/or obtaining debt financing and attaining future
profitable operations. Management’s plans include selling our equity securities
and obtaining debt financing to fund our capital requirements and ongoing
operations; however, there was is assurance we will be successful in these
efforts.





Item 7.   Financial Statements





Index to
Financial Statements:





Audited
      Financial Statements:F-1
            Report of Independent Registered Public Accounting
      FirmF-2
            Balance Sheet as of November 30, 2007F-3
            Statements of Operations – Period from inception (March 28,
      2006) to November 30, 2007F-4
            Statement of Stockholders’ Equity (Deficit) from inception
      (March 28, 2006) to November 30, 2007F-5
            Statements of Cash Flows for the period from inception (March
      28, 2006) to November 30, 2007F-6
            Notes to Financial
Statements




17
 Table of Contents




MOORE
& ASSOCIATES, CHARTERED
 ACCOUNTANTS AND
ADVISORS
 PCAOB REGISTERED
 
 
 REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
 
 To
the Board of Directors
 RM
Health International Inc
 (A
Development Stage Company)
 
 
 We have
audited the accompanying balance sheets of RM Health International Inc (A
Development Stage Company) as of November 30, 2007 and November 30, 2006, and
the related statements of operations, stockholders’ equity and cash flows for
the years ended November 30, 2007 and November 30, 2006 and since inception on
March 28, 2006 through November 30, 2007. These financial statements are the
responsibility of the Company’s management.  Our responsibility is to
express an opinion on these financial statements based on our
audits.
 
 We
conducted our audits in accordance with standards of the Public Company
Accounting Oversight Board (United States).  Those standards require
that we plan and perform the audits to obtain reasonable assurance about whether
the financial statements are free of material misstatement.  An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements.  An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement
presentation.  We believe that our audits provide a reasonable basis
for our opinion.
 
 In our
opinion, the financial statements referred to above present fairly, in all
material respects, the financial position of RM Health International Inc (A
Development Stage Company) as of November 30, 2007 and November 30, 2006, and
the related statements of operations, stockholders’ equity and cash flows for
the years ended November 30, 2007 and November 30, 2006 and since inception on
March 28, 2006 through November 30, 2007, in conformity with accounting
principles generally accepted in the United States of America.
 
 The
accompanying financial statements have been prepared assuming that the Company
will continue as a going concern.  As discussed in Note 3 to the
financial statements, the Company has accumulated deficit of $24,448 as of
November 30, 2007, which raises substantial doubt about its ability to continue
as a going concern.  Management’s plans concerning these matters are
also described in Note 3.  The financial statements do not include any
adjustments that might result from the outcome of this uncertainty.
 
 /s/
Moore & Associates, Chartered
 Moore
& Associates Chartered
 Las
Vegas, Nevada
 February
29, 2008
 
 2675 S. Jones Blvd. Suite
109, Las Vegas, NV 89146 (702) 253-7499 Fax (702) 253-7501


F-1
 Table of Contents


RM
HEALTH INTERNATIONAL, INC. (A Development Stage Company) Balance Sheets
  ASSETSNovember
      30,2007
                
                November
      30,2006CURRENT
      ASSETSCash
      and cash equivalents
                $
                10,775
                
                $
                23,995Deposits
                
                1,000
                
                
                -Total
      Current Assets
                
                11,775
                
                
                23,995TOTAL
      ASSETS
                $
                11,775
                
                $
                23,995LIABILITIES AND
      STOCKHOLDERS' EQUITYCURRENT
      LIABILITIESAccounts
      payable and accrued liabilities
                $
                788
                
                $
                3,650Due
      to related party
                
                9,750
                
                
                3,000Total
      Current Liabilities
                
                10,538
                
                
                6,650STOCKHOLDERS'
      EQUITYCommon
      stock - $0.001 par value; 75,000,000 sharesauthorized;
      6,759,300 shares issued and outstanding
                
                6,759
                
                
                6,759Additional
      paid-in capital
                
                20,926
                
                
                20,926Accumulated
      deficit
                
                (26,448)
                
                
                (10,340)Total
      Stockholders' Equity
                
                1,237
                
                
                17,345TOTAL
      LIABILITIES AND STOCKHOLDERS'  EQUITY
                $
                11,775
                
                $
                23,995
 The
accompanying notes are an integral part of these financial
statements.
  Table of Contents
 RM
HEALTH INTERNATIONAL, INC. (A Development Stage Company) Statements of Operations
 For
      theYear
      Ended
                    November
      30,2007
                
                From
      Inceptionon March
      28,2006
      ThroughNovember
      30,2006
                
                From
      Inceptionon March
      28,2006
      ThroughNovember
      30,2007REVENUES
                $
                -
                
                $
                -
                
                $
                -COST
      OF REVENUES
                
                -
                
                
                -
                
                
                -GROSS
      MARGIN
                
                -
                
                
                -
                
                
                -OPERATING
      EXPENSESOrganization
      costs
                
                -
                
                
                375
                
                
                375General
      and administrative
                
                16,108
                
                
                9,965
                
                
                26,073Total
      Operating Expenses
                
                16,108
                
                
                10,340
                
                
                26,448NET
      LOSS
                $
                (16,108)
                
                $
                (10,340)
                
                $
                (26,448)BASIC
      LOSS PER SHARE
                $
                (0.00)
                
                $
                (0.00)WEIGHTED
      AVERAGE NUMBEROF SHARES OUTSTANDING
                
                6,759,300
                
                
                5,366,114
 The
accompanying notes are an integral part of these financial
statements.
  F-3
 Table of Contents
 RM
HEALTH INTERNATIONAL, INC. (A Development Stage Company) Statements of Stockholders' Equity
 Common
      Stock

                    Shares                        
      Amount
                
                AdditionalPaid-In

                    Capital
                
                Accumulated

                    Deficit
                
                
                TotalBalance
      March 28, 2006
                -
                
                $
                -
                
                $
                -
                
                $
                -
                
                $
                -Shares
      issued for cash, April2006, at $0.001 per
      share
                3,200,000
                
                
                3,200
                
                
                -
                
                
                -
                
                
                3,200Shares
      issued for cash, May2006, at $0.005 per
      share
                1,950,000
                
                
                1,950
                
                
                7,800
                
                
                -
                
                
                9,750Shares
      issued for cash, July2006, at $0.005 per
      share
                1,575,000
                
                
                1,575
                
                
                6,300
                
                
                -
                
                
                7,875Shares
      issued for cash, July2006, at $0.20 per
share
                22,500
                
                
                22
                
                
                4,478
                
                
                -
                
                
                4,500Shares
      issued for cash, August2006, at $0.20 per
      share
                11,800
                
                
                12
                
                
                2,348
                
                
                -
                
                
                2,360Net
      loss from inceptionthrough November 30, 2006
                -
                
                
                -
                
                
                -
                
                
                (10,340)
                
                
                (10,340)Balance,
      November 30, 2006
                6,759,300
                
                
                6,759
                
                
                20,926
                
                
                (10,340)
                
                
                17,345Net
      loss for the yearended November 30,
2007
                -
                
                
                -
                
                
                -
                
                
                (16,108)
                
                
                (16,108)Balance,
      November 30, 2007
                6,759,300
                
                $
                6,759
                
                $
                20,926
                
                $
                (26,448)
                
                $
                1,237
 The
accompanying notes are an integral part of these financial
statements.
  F-4
 Table of Contents
 RM
HEALTH INTERNATIONAL, INC.
 (A Development Stage Company) Statements of Cash Flows


For
      theYear
      Ended
                November
      30,
                2007
              
              From
      Inceptionon March
      28,2006
      ThroughNovember 30,

                  2006
              
              From
      Inceptionon March
      28,2006
      ThroughNovember 30,

                  2007CASH
      FLOWS FROMOPERATING
      ACTIVITIESNet
      loss
              $
              (16,108)
              
              $
              (10,340)
              
              $
              (26,448)Adjustments
      to reconcile net loss tonet
      cash used by operating activities:Changes
      in working capital items:Deposits
              
              (1,000)
              
              
              -
              
              
              (1,000)Accounts
      payable and accrued liabilities
              
              (2,862)
              
              
              3,650
              
              
              788Net
      Cash Used byOperating
      Activities
              
              (19,970)
              
              
              (6,690)
              
              
              (26,660)CASH
      FLOWS FROMINVESTING
      ACTIVITIES
              
              -
              
              
              -
              
              
              -CASH
      FLOWS FROMFINANCING
      ACTIVITIESIncrease
      in due to related party
              
              6,750
              
              
              3,000
              
              
              9,750Proceeds
      from issuance of common stock
              
              -
              
              
              27,685
              
              
              27,685Net
      Cash Provided byFinancing
      Activities
              
              6,750
              
              
              30,685
              
              
              37,435NET
      DECREASE IN CASH
              
              (13,220)
              
              
              23,995
              
              
              10,775CASH
      AT BEGINNING OF PERIOD
              
              23,995
              
              
              -
              
              
              -CASH
      AT END OF PERIOD
              $
              10,775
              
              $
              23,995
              
              $
              10,775SUPPLEMENTAL
      DISCLOSURES OFCASH
      FLOW INFORMATIONCASH
      PAID FOR:Interest
              $
              -
              
              $
              -
              
              $
              -Income
      Taxes
              $
              -
              
              $
              -
              
              $
              -


The
accompanying notes are an integral part of these financial
statements.
  F-5
 Table of Contents


RM
HEALTH INTERNATIONAL, INC.


(A
Development Stage Company)
 Notes to Financial Statements
 November
30, 2007 and 2006
  1.           
SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES
 
 Nature of
Business
 The
Company was incorporated in the State of Nevada, United States of America on
March 28, 2006 and its fiscal year end is November 30. The Company is involved
in sales and distribution of natural health and supplemental products through
the Internet.
 
 Use of
Estimates
 The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts of
revenue and expenses during the reporting period. Actual results could differ
from those estimates.
 
 Basic (Loss) per Common
Share
  Basic
(loss) per share is calculated by dividing the Company’s net loss applicable to
common shareholders by the weighted average number of common shares during the
period. Diluted earnings per share is calculated by dividing the Company’s net
income available to common shareholders by the diluted weighted average number
of shares outstanding during the year. The diluted weighted average number of
shares outstanding is the basic weighted number of shares adjusted for any
potentially dilutive debt or equity. There are no such common stock equivalents
outstanding as of November 30, 2007 and 2006.




For
      the
              Year
      Ended
              November
      30,
              2007
            
            From
      Inception
              on
      March 28,
              2006
      Through
              November
      30,
              2006Loss
      (numerator)
            $
            (16,108)
            
            $
            (10,340)Shares
      (denominator)
            
            6,759,300
            
            
            5,366,114Per
      share amount
            $
            (0.00)
            
            $
            (0.00)




Dividends


The
Company has not adopted any policy regarding payment of dividends. No dividends
have been paid during any of the periods shown.




Comprehensive
Income


The
Company has no component of other comprehensive income. Accordingly, net income
equals comprehensive income for the period ended November 30, 2007.




Advertising
Costs


The
Company’s policy regarding advertising is to expense advertising when incurred.
The Company had not incurred any advertising expense as of November 30,
2007.





F-6
 Table of Contents


RM
HEALTH INTERNATIONAL, INC.
 (A
Development Stage Company)
 Notes
to Financial Statements
 November
30, 2007 and 2006
  1.           SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES (Continued)
 
 Cash and Cash
Equivalents
 For
purposes of the Statement of Cash Flows, the Company considers all highly liquid
instruments purchased with a maturity of three months or less to be cash
equivalents to the extent the funds are not being held for investment
purposes.
 
 Income
Taxes
 The
Company provides for income taxes under Statement of Financial Accounting
Standards No. 109, Accounting for Income Taxes. SFAS No. 109 requires the use of
an asset and liability approach in accounting for income taxes. Deferred tax
assets and liabilities are recorded based on the differences between the
financial statement and tax bases of assets and liabilities and the tax rates in
effect when these differences are expected to reverse. The Company’s predecessor
operated as entity exempt from Federal and State income taxes.
 
 SFAS No.
109 requires the reduction of deferred tax assets by a valuation allowance if,
based on the weight of available evidence, it is more likely than not that some
or all of the deferred tax assets will not be realized.
 
 The
provision for income taxes differs from the amounts which would be provided by
applying the statutory federal income tax rate of 39% to the net loss before
provision for income taxes for the following reasons:


November
      30, 2007
              
              November
      30, 2006Income
      tax expense at statutory rate
              $
              (6,282)
              
              $
              (4,033)Common
      stock issued for services
              
              -
              
              
              -Valuation
      allowance
              
              6,282
              
              
              4,033Income
      tax expense per books
              $
              -
              
              $
              -
 
 Net
deferred tax assets consist of the following components as of:
 
 December
      31, 2007
              
              December
      31, 2006NOL
      carryover
              $
              10,315
              
              $
              4,033Valuation
      allowance
              
              (10,315)
              
              
              (4,033)Net
      deferred tax asset
              $
              -
              
              $
              -
 Due to
the change in ownership provisions of the Tax Reform Act of 1986, net operating
loss carry forwards of $26,448 for federal income tax reporting purposes are
subject to annual limitations. Should a change in ownership occur net operating
loss carry forwards may be limited as to use in future years.
 
 Impairment of Long-Lived
Assets
 The
Company continually monitors events and changes in circumstances that could
indicate carrying amounts of long-lived assets may not be recoverable. When such
events or changes in circumstances are present, the Company assesses the
recoverability of long-lived assets by determining whether the carrying value of
such assets will be recovered
 F-7
 Table of Contents
 RM
HEALTH INTERNATIONAL, INC.
 (A
Development Stage Company)
 Notes
to Financial Statements
 November
30, 2007 and 2006
 1.           SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES (Continued)
 
 Impairment of Long-Lived
Assets (Continued)
 through
undiscounted expected future cash flows. If the total of the future cash flows
is less than the carrying amount of those assets, the Company recognizes an
impairment loss based on the excess of the carrying amount over the fair value
of the assets. Assets to be disposed of are reported at the lower of the
carrying amount or the fair value less costs to sell.
 
 Accounting
Basis
 The basis
is accounting principles generally accepted in the United States of
America.  The Company has adopted a November 30 fiscal year
end.
 
 Stock-based
compensation.
 As of
November 30, 2007, the Company has not issued any share-based payments to its
employees.
 
 The
Company adopted SFAS No. 123-R effective January 1, 2006 using the
modified prospective method. Under this transition method, stock compensation
expense includes compensation expense for all stock-based compensation awards
granted on or after January 1,2006, based on the grant-date fair value
estimated in accordance with the provisions of SFAS No. 123-R.
 
 Recent Accounting
Pronouncements
 In
September 2006, the FASB issued SFAS No. 157, Fair Value Measurements,
which defines fair value, establishes a framework for measuring fair value in
generally accepted accounting principles, and expands disclosures about fair
value measurements. SFAS No. 157 does not require any new fair value
measurements, but provides guidance on how to measure fair value by providing a
fair value hierarchy used to classify the source of the information. This
statement is effective for us beginning January 1, 2008. The Company is
currently assessing the potential impact that adoption of SFAS No. 157
would have on the financial statements.
 
 In
February 2007, the FASB issued SFAS No. 159, The Fair Value Option for
Financial Assets and Financial Liabilities. SFAS No. 159 gives the
irrevocable option to carry many financial assets and liabilities at fair
values, with changes in fair value recognized in earnings. SFAS No. 159 is
effective beginning January 1, 2008, although early adoption is permitted.
The Company is currently assessing the potential impact that adoption of SFAS
No. 159 will have on the financial statements.
 
 The FASB
has revised SFAS No. 141.  This revised statement establishes uniform
treatment for all acquisitions.  It defines the acquiring
company.  The statement further requires an acquirer to recognize the
assets acquired, the liabilities assumed, and any non-controlling interest in
the acquired at the acquisition date, measured at their fair market values as of
that date.  It requires the acquirer in a business combination
achieved in stages to recognize the identifiable assets and liabilities, as well
as the non-controlling interest in the acquired, at the full amounts of their
fair values. This changes the way that
  F-8
 Table of Contents
 RM
HEALTH INTERNATIONAL, INC.
 (A
Development Stage Company)
 Notes
to Financial Statements
 November
30, 2007 and 2006
  1.           SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES (Continued)
  Recent Accounting Pronouncements
(Continued)
 minority
interest is recorded and modified as a parent’s interest in a subsidiary changes
over time.  This statement also makes corresponding significant
amendments to other standards that related to business combinations, namely,
109, 142 and various EITF’s.  This statement applies prospectively to
business combinations for which the acquisition date is on or after the
beginning of the first annual reporting period beginning on or after December
15, 2008.  The Company believes the implementation of this standard
will have no effect on our financial statements.
 
 Revenue
Recognition
 The
Company recognizes revenue when products are fully delivered or services have
been provided and collection is reasonably assured.
 
 Deposits
 Deposits
are advance payments on future purchases of inventory.
 
 2.           COMMON STOCK
 
 The
total number of common shares authorized that may be issued by the Company is
75,000,000 shares with a par value of one tenth of one cent ($0.001) per share
and no other class of shares is authorized.
  During the period from March 28, 2006 (Inception) to November 30, 2006, the
Company issued 6,759,300 shares of common stock for total proceeds of
$27,685.
  To November 30, 2007, the Company has not granted any stock options and has not
recorded any stock-based compensation.
 
 3.           GOING
CONCERN
 The
accompanying financial statements have been prepared in conformity with
generally accepted accounting principle, which contemplate continuation of the
Company as a going concern.  However, the Company has accumulated
deficit of $26,448 as of November 30, 2007.  The Company currently has
limited liquidity, and has not completed its efforts to establish a stabilized
source of revenues sufficient to cover operating costs over an extended period
of time which raises substantial doubt about its ability to continue as a going
concern.
 
 Management
anticipates that the Company will be dependent, for the near future, on
additional investment capital to fund operating expenses The Company intends to
position itself so that it may be able to raise additional funds through the
capital markets. In light of management’s efforts, there are no assurances that
the Company will be successful in this or any of its endeavors or become
financially viable and continue as a going concern.
 
 4.           DUE TO RELATED
PARTY
 The
Company has received cash advances from shareholders which are non interest
bearing, unsecured and due upon demand. The Company owes $9,750 for such
advances as of December 31, 2007.


F-9
 Table of Contents


Item
8.   Changes In and Disagreements with Accountants on Accounting
and FinancialDisclosure
 
 No events
occurred requiring disclosure under Item 304(b) of Regulation S-B during the
fiscal year ending November 30, 2007.
 
 Item 8A.  Controls and Procedures
 
 We
carried out an evaluation of the effectiveness of the design and operation of
our disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) as of November 30, 2007.  This evaluation was
carried out under the supervision and with the participation of our Chief
Executive Officer and Chief Financial Officer, Mr. Randy Weston. Based upon that
evaluation, our Chief Executive Officer and Chief Financial Officer concluded
that, as of November 30, 2007, our disclosure controls and procedures are
effective.  There have been no significant changes in our internal
controls over financial reporting during the year ended november 30, 2007 that
have materially affected or are reasonably likely to materially affect such
controls.
 
 Disclosure
controls and procedures are controls and other procedures that are designed to
ensure that information required to be disclosed in our reports filed or
submitted under the Exchange Act are recorded, processed, summarized and
reported, within the time periods specified in the SEC's rules and forms.
Disclosure controls and procedures include, without limitation, controls and
procedures designed to ensure that information required to be disclosed in our
reports filed under the Exchange Act is accumulated and communicated to
management, including our Chief Executive Officer and Chief Financial Officer,
to allow timely decisions regarding required disclosure.
 
 Limitations on the
Effectiveness of Internal Controls
 
 Our
management does not expect that our disclosure controls and procedures or our
internal control over financial reporting will necessarily prevent all fraud and
material error. Our disclosure controls and procedures are designed to provide
reasonable assurance of achieving our objectives and our Chief Executive Officer
and Chief Financial Officer concluded that our disclosure controls and
procedures are effective at that reasonable assurance level.  Further,
the design of a control system must reflect the fact that there are resource
constraints, and the benefits of controls must be considered relative to their
costs. Because of the inherent limitations in all control systems, no evaluation
of controls can provide absolute assurance that all control issues and instances
of fraud, if any, within our company have been detected. These inherent
limitations include the realities that judgments in decision-making can be
faulty, and that breakdowns can occur because of simple error or mistake.
Additionally, controls can be circumvented by the individual acts of some
persons, by collusion of two or more people, or by management override of the
internal control. The design of any system of controls also is based in part
upon certain assumptions about the likelihood of future events, and there can be
no assurance that any design will succeed in achieving its stated goals under
all potential future conditions. Over time, control may become inadequate
because of changes in conditions, or the degree of compliance with the policies
or procedures may deteriorate.




18
 Table of Contents




Item 8B.  Other information





None.




PART III





Item
9.  Directors, Executive Officers, Promoters and Control Persons;
Compliance withSection
16(a) of the Exchange Act





The
following information sets forth the names of our directors and executive
officers, their ages and their positions as of November 30, 2007.





Name
            Age
            Position
      Held with the Company
            Date
      First Elected or AppointedRandy
      Weston
            43
            President,
      Chief Executive Officer, Chief Financial Officer, Principal Accounting
      Officer, Secretary, Treasurer, Director
            March
      28, 2006





Set forth
below is a brief description of the background and business experience of each
of our executive officers and directors.





Randy Weston is our President,
Secretary, Treasurer and a director. As President, Mr. Weston is responsible for
the day-to-day management of the Company.





Prior to
joining RM Health International, Mr. Weston accumulated more than 15 years of
general business experience primarily in the field of sales and brokerage of
automobiles, boats, and motorcycles, a line of business Mr. Weston pursued in
addition to his career as a professional pilot. Mr. Weston is presently employed
as a pilot for Terrible Herbst, Inc. which began in November
2004.  Previously, he was employed by Air Atlanta, Iceland, as a
Captain on a B767 from March 2003 - March 2004; by National Airlines, Las Vegas,
Nevada, as a Captain on a B757 from November 1999 - November 2002; by Air
Wisconsin Airlines, Appleton, Wisconsin, as a Captain on a CRJ from March 1997 -
November 1999; by Air Vegas Airlines, Las Vegas, Nevada, as a Captain on CRJ
from March 1996 - March 1997; and by Air BC Richmond, British Columbia, as a
Pilot on a DHC8 from May 1990 - April 1995.





Term
of Office





Our
directors are appointed for a one-year term to hold office until the next annual
meeting of our shareholders or until removed from office in accordance with our
bylaws.





Our
executive officers are appointed by our board of directors and hold office until
removed by




19
 Table of Contents




the
board.





Significant
Employees





As of
November 30 2007, we had no significant employees other than our officers and
directors.





Family
Relationships





As of
November 30, 2007, there were no family relationships between or among the
directors, executive officers or persons nominated or chosen by us to become
directors or executive officers.





Involvement
in Certain Legal Proceedings





To  the
best of our knowledge, during the past five years, none of the
following  occurred with  respect to a present
director,  person nominated to become director, executive officer,
or  control person as of November 30,
2007:  (1)  any bankruptcy petition filed by or against any
business of which such person was a general partner or executive officer either
at  the  time  of the bankruptcy or within two
years prior to that time; (2) any conviction in a
criminal  proceeding  or  being subject to a
pending criminal proceeding (excluding  traffic  violations
and other minor offenses); (3) being subject to any order, judgment or decree,
not subsequently reversed, suspended or  vacated, of  any
court  of  competent  jurisdiction,  permanently  or
temporarily enjoining, barring, suspending or otherwise limiting his or her
involvement in  any  type of business, securities or banking
activities; and (4) being found
by  a  court  of  competent  jurisdiction  (in  a  civil
action), the SEC or the
Commodities  Futures  Trading  Commission to have
violated a federal or state securities or commodities law, and the judgment has
not been reversed, suspended or vacated.





Audit
Committee





As of
november 30, 2007, we did not have a separately-designated standing audit
committee.  The entire board of directors performed the functions of
an audit committee, but no written charter governed the actions of the board of
directors when performing the functions that would generally be performed by an
audit committee. The board of directors approved the selection of our
independent accountants and met and interacted with the independent accountants
to discuss issues related to financial reporting. In addition, the board of
directors reviewed the scope and results of the audit with the independent
accountants, reviewed with management and the independent accountants our annual
operating results, considered the adequacy of our internal




20
 Table of Contents




accounting
procedures and considered other auditing and accounting matters including fees
to be paid to the independent auditor and the performance of the independent
auditor.




We did
not have an audit committee financial expert as of November 30, 2007 because of
the size of our company and our board of directors at this
time.  We believed that we did not require an audit committee
financial expert at thst time because we retained outside consultants who
possessed these attributes.





For the
fiscal year ending November 30, 2007, the board of directors:





1.
            Reviewed
      and discussed the audited financial statements with management,
      and





2.
            Reviewed
      and discussed the written disclosures and the letter from our independent
      auditors on the matters relating to the auditor's
      independence.





Based
upon the board of directors’ review and discussion of the matters above, the
board of directors authorized inclusion of the audited financial statements for
the year ended May 31, 2007 to be included in this Annual Report on Form 10-KSB
and filed with the Securities and Exchange Commission.





Section
16(a) Beneficial Ownership Reporting Compliance





Our
officers, directors and shareholders owning greater than ten percent of our
shares are not required to comply with Section 16(a) of the Securities Exchange
Act of 1934 because we do not have a class of securities registered under
Section 12 of the Securities Exchange Act of 1934.





Code
of Ethics Disclosure





As of
November 30, 2007, we have not adopted a Code of Ethics for Financial
Executives, which include our principal executive officer, principal financial
officer, principal accounting officer or controller, or persons performing
similar functions.





Item 10.  Executive Compensation





Compensation
Discussion and Analysis





Currently,
our sole officer and director, Randy Weston, does not receive any cash or other
compensation for his services to the company.  Because we are a
development stage company with limited operations and capital resources, we are
unable to compensate him.  Mr. Weston owns a relatively large
proportion of the company’s issued and outstanding common stock, however, and
serves as the sole officer and director due to his entrepreneurial interest in
our development and long term success.





21
 Table of Contents




Summary
Compensation Table




The table
below summarizes all compensation awarded to, earned by, or paid to our former
or current executive officers for the fiscal year ended November 30,
2007.





SUMMARY
      COMPENSATION TABLEName
              and
              principal
              position
            Year
            Salary
              ($)
            Bonus
              ($)
            Option
              Awards
              ($)
            Non-Equity
              Incentive
      Plan
              Compensation
              ($)
            Nonqualified
              Deferred
              Compensation
              Earnings
      ($)
            All
      Other
              Compensation
              ($)
            Total
              ($)Randy
      Weston, President, CEO, CFO, and Director
            2007
              2006
            0
              0
            0
              0
            0
              0
            0
              0
            0
              0
            0
              0
            0
              0





Narrative
Disclosure to the Summary Compensation Table




We did
not compensate our executive officers for services rendered during the fiscal
year ended November 30, 2007.





Outstanding
Equity Awards at Fiscal Year-End





The table
below summarizes all unexercised options, stock that has not vested, and equity
incentive plan awards for each named executive officer as of November 30,
2007.





OUTSTANDING
      EQUITY AWARDS AT FISCAL YEAR-ENDOPTION
      AWARDS
            STOCK
      AWARDSName
            Number
      of
              Securities
              Underlying
              Unexercised
              Options
              (#)
              Exercisable
            Number
      of
              Securities
              Underlying
              Unexercised
              Options
              (#)
              Unexercisable
            Equity
              Incentive
              Plan
              Awards:
              Number
      of
              Securities
              Underlying
              Unexercised
              Unearned
              Options
              (#)
            Option
              Exercise
              Price
              ($)
            Option
              Expiration
              Date
            Number
              of
              Shares
              or
      Units
              of
              Stock
      That
              Have
              Not
              Vested
              (#)
            Market
              Value
              of
              Shares
              or
              Units
              of
              Stock
              That
              Have
              Not
              Vested
              ($)
            Equity
              Incentive
              Plan
              Awards:
              Number
              of
              Unearned
              Shares,
              Units
      or
              Other
              Rights
              That
      Have
              Not
              Vested
              (#)
            Equity
              Incentive
              Plan
              Awards:
              Market
      or
              Payout
              Value
      of
              Unearned
              Shares,
              Units
      or
              Other
              Rights
              That
              Have
      Not
              Vested
              (#)Randy
      Weston
            -
            -
            -
            -
            -
            -
            -
            -
            -





22
 Table of Contents




Compensation
of Directors





The table
below summarizes all compensation of our directors as of November 30,
2007.





DIRECTOR
      COMPENSATIONName
            Fees
      Earned or
              Paid
      in
              Cash
              ($)
            Stock
      Awards
              ($)
            Option
              Awards
              ($)
            Non-Equity
              Incentive
              Plan
              Compensation
              ($)
            Non-Qualified
              Deferred
              Compensation
              Earnings
              ($)
            All
              Other
              Compensation
              ($)
            Total
              ($)Randy
      Weston
            -
            -
            -
            -
            -
            -
            -





Narrative
Disclosure to the Director Compensation Table





We do not
pay any cash or other compensation to our directors.





Item
11.  Security Ownership of Certain Beneficial Owners and Management
and RelatedStockholder
Matters





The
following table sets forth, as of November 30, 2007, the beneficial ownership of
our common stock by each executive officer and director, by each person known by
us to beneficially own more than 5% of the our common stock and by the executive
officers and directors as a group.  Except as otherwise indicated, all
shares are owned directly and the percentage shown is based on 6,759,300 shares
of common stock issued and outstanding on November 30, 2007.





Name
      of Beneficial Owners of Common Stock1
            Title
      of Class
            Amount
      and Nature of Beneficial Ownership
            %
      of Common StockRandy
      Weston
              President,
      Chief Executive Officer, Chief Financial Officer, Principal Accounting
      Officer, Secretary, Treasurer, Director
            Common
      Stock
            3,200,000
            47.34%DIRECTORS
      AND OFFICERS - TOTAL
            
            3,200,000
            47.34%5%
      SHAREHOLDERSNone.




(1)
            As
      used in this table, "beneficial ownership" means the sole or shared power
      to vote, or to direct the voting of, a security, or the sole or shared
      investment power with respect to a security (i.e., the power to dispose
      of, or to direct the disposition of, a security). In addition, for
      purposes of this table, a person is deemed, as of any date, to have
      "beneficial ownership" of any security that such person has the right to
      acquire within 60 days after such
date.






23
 Table of Contents




Item 12.   Certain Relationships and Related
Transactions





As of
November 30, 2007, none of our directors or executive officers, nor any proposed
nominee for election as a director, nor any person who beneficially owns,
directly or indirectly, shares carrying more than 5% of the voting rights
attached to all of our outstanding shares, nor any members of the immediate
family (including spouse, parents, children, siblings, and in-laws) of any of
the foregoing persons had any material interest, direct or indirect, in any
transaction over the last two years or in any presently proposed transaction
which, in either case, has or will materially affect us:





Item
13.   Exhibits





Exhibit
      Number
            Description3.1
            Articles
      of Incorporation, as amended (1)3.2
            By-laws,
      as amended (1)31.1
            Certification of Chief Executive Officer pursuant to
      Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to
      Section 302 of the Sarbanes-Oxley Act of 200231.2
            Certification of Chief Financial Officer pursuant to
      Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to
      Section 302 of the Sarbanes-Oxley Act of 200232.1
            Certification of Chief Executive Officer and Chief
      Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant
      to Section 906 of the Sarbanes-Oxley Act of
  2002





(1)
            Incorporated
      by reference to the Registration Statement on Form SB-2 filed with the
      Securities and Exchange Commission on February 5,
  2007.




24
 Table of Contents




Item 14.   Principal Accountant Fees and
Services





Audit
Fees




The
aggregate fees billed by our auditors for professional services rendered in
connection with a review of the financial statements included in our quarterly
reports on Form 10-QSB and the audit of our annual consolidated financial
statements for the fiscal year ended November 30, 2007 (our fist full fiscal
year) was approximately $8,250.00.




Audit-Related
Fees




Our
auditors did not bill any additional fees for assurance and related services
that are reasonably related to the performance of the audit or review of our
financial statements.




Tax Fees




The
aggregate fees billed by our auditors for professional services for tax
compliance, tax advice, and tax planning were $0 and $0 for the fiscal years
ended November 30, 2007 and 2006.




All Other Fees




The
aggregate fees billed by our auditors for all other non-audit services, such as
attending meetings and other miscellaneous financial consulting, for the fiscal
years ended November 30, 2007 and 2006 were $0 and $0 respectively.




25
 Table of Contents




SIGNATURES




In
accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.





RM
Health International, Inc.





By: 
/s/ Randy Weston


Randy
Weston


Chief
Executive Officer and


Chief
Financial Officer, and Principal Accounting Officer


Dated:
February 28, 2008